Sarepta dives deeper into gene therapy
Cell & Gene Therapy 2018
Making sure everyone with DMD gets access to treatments and the ‘essential’ interventions that can make life worth living is key.
Santhera is putting patient needs at the heart of its rare disease speciality business. Chief Executive Officer Thomas Meier, PhD, talks about the company’s mission – and how rationalising Europe’s drug review systems could help patients.